Ilesol Pharmaceuticals

What Ilesol Pharmaceuticals does

Ilesol Pharmaceuticals is a private, for-profit pharmaceutical manufacturer founded in 2017 and headquartered in Varazdin, Croatia. Per its own short description, the company produces and distributes white-label CBD and CBG products, positioning itself as a contract / private-label manufacturer serving brand customers that want to sell cannabinoid-based offerings under their own labels without owning production assets.

The company operates with a headcount in the 11–50 range and is led by Sasha Bajilo, who serves as both CEO and Founder. Its business model is B2B contract manufacturing: it earns revenue by producing finished or semi-finished CBD and CBG products on behalf of third-party brand owners, rather than selling directly to end consumers under its own consumer brand. No specific products, pricing, customer logos, distribution channels, certifications, patents, or partnerships were disclosed in the available source data, and the company's own webpage reportedly displayed only a loader/verification page with no substantive content during the data collection window.

Strategically, Ilesol is a small, EU-based, vertically focused white-label manufacturer in a category — legal cannabinoid APIs and finished products — that has been subject to evolving regulatory frameworks across the EU. The combination of low-cost Croatian manufacturing, pharmaceutical positioning, and a white-label go-to-market suggests a strategy aimed at cost-competitive supply to European brand owners. However, the absence of disclosed revenue, funding history, customer references, and product specifics limits visibility into scale, growth, and competitive positioning beyond the firm's own self-description.

Name

Ilesol Pharmaceuticals

Website

https://ilesol.com

Company type

Private

Founded year

2017

Headcount range

11–50 employees

Short description

Ilesol Pharmaceuticals is a private Croatian pharmaceutical manufacturer founded in 2017 that produces and distributes white-label CBD and CBG products on a B2B contract manufacturing basis for brand-owner customers, led by CEO and Founder Sasha Bajilo.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceutical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industries

CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles) (CRANAHAA), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• White-label CBD manufacturing
• Cannabinoid product manufacturing
• Private label supplements
• Pharmaceutical contract manufacturing
• CBG product production

Headquarters

HQ city

Varazdin

HQ country

Croatia

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Ilesol Pharmaceuticals manufactures and distributes white-label CBD (cannabidiol) and CBG (cannabigerol) products. The company produces cannabinoid-based formulations and finished products that other brands can market and sell under their own private labels.

Differentiator

Problem solved

Functional benefit

Products and services

• White-label CBD products
• White-label CBG products

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Pharmahemp: Slovenia-based CBD manufacturer specializing in white-label and bulk CBD/CBG products distributed across the EU. Directly comparable given regional proximity, white-label business model, and similar product portfolio.
• Endoca: Denmark-based CBD manufacturer producing hemp-derived CBD extracts and finished products, including white-label offerings. Comparable to Ilesol as a European-focused CBD manufacturer with similar botanical extraction and finished-product capabilities.
• Kazmira: US-based CBD isolate and finished-product white-label manufacturer serving brand customers globally. Comparable in pure-play white-label manufacturing model and focus on bulk cannabinoid supply.
• HemPoland: Polish CBD/CBDA manufacturer producing bulk cannabinoid ingredients and finished white-label products for the European market. Closely comparable in scale, geography, and white-label manufacturing focus.
• Global Cannabinoids: US-based bulk and white-label CBD/CBG manufacturer supplying finished cannabinoid products to brands. Comparable white-label/CBD-CBG manufacturing focus, though geographically North American.
• Elixinol: Global CBD manufacturer and brand operator producing hemp-derived CBD extracts and finished products including white-label/B2B supply. Comparable in combining cannabinoid manufacturing with branded and partner products.

Broad incumbents

• Charlotte's Web Holdings: Largest US-focused CBD brand and manufacturer. Comparable in manufacturing hemp-derived cannabinoid products, but operates at much larger scale and is brand-led rather than white-label-only.
• Mile High Labs: Large-scale US CBD isolate and finished-product manufacturer with significant extraction capacity and white-label services. Comparable as a white-label CBD manufacturer but operates at materially greater scale.

Regional players

• Flora Fusion: European CBD manufacturer producing cannabinoid extracts and finished products for B2B customers. Comparable regional CBD manufacturer serving overlapping European buyers with similar extract and finished-product offerings.

Others

• European Industrial Hemp Association: Industry association representing European hemp and CBD processors and manufacturers. Relevant ecosystem participant for a European CBD manufacturer tracking regulatory developments and industry standards.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ilesol Pharmaceuticals